ImmunityBio’s Clinical Pipeline Gains Momentum with Key Data and Regulatory Progress

ImmunityBio US45256X1037

ImmunityBio is currently demonstrating significant clinical and regulatory advancements across its immunotherapy development portfolio. The biotechnology firm is advancing multiple promising oncology programs, with its lead asset ANKTIVA serving as a cornerstone alongside several investigational studies targeting various cancer types.

Regulatory developments are providing substantial momentum. Following a meeting with the U.S. Food and Drug Administration (FDA) on January 20, ImmunityBio is to submit supplemental information within a 30-day period for the resubmission of ANKTIVA in papillary bladder cancer. The agency has indicated that new clinical trials will not be required for this application.

Internationally, ANKTIVA received two accelerated approvals in Saudi Arabia during January. The clearances cover its use in non-muscle invasive bladder cancer with carcinoma in situ, as well as in combination with checkpoint inhibitors for metastatic non-small cell lung cancer.

Encouraging Clinical Data Across Oncology Indications

Recent clinical readouts have highlighted the potential of the company's pipeline. In late January, survival data from the Phase 2 QUILT-3.078 trial in recurrent glioblastoma were presented. As of the January 22 cutoff date, 19 of the 23 treated patients remained alive. The longest evaluable survival duration was twelve months and ongoing, while a median overall survival was not yet reached—a positive indicator for this difficult-to-treat condition.

On February 2, the company initiated a Phase 2 trial, designated ResQ215B, for patients with indolent B-cell non-Hodgkin lymphoma, including Waldenström macroglobulinemia. A key differentiator of this combination therapy—comprising CAR-NK cells, ANKTIVA, and rituximab—is its omission of lymphodepleting chemotherapy, a standard component in conventional CAR-T treatments.

This study builds upon promising Phase 1 results. In an initial cohort of four Waldenström patients, disease control was achieved in all cases. Two of those patients attained complete remissions, which remained durable at seven and fifteen months, respectively.

Financial Performance and Analyst Sentiment

Preliminary product revenue for 2025 reached approximately $113 million, representing a sevenfold increase, or 700%, over the prior year. This substantial commercial growth prompted several equity researchers to revise their price targets upward. HC Wainwright adjusted its target to $10, while BTIG set a $9 objective.

The upcoming months are poised to be eventful. With an impending FDA submission in bladder cancer and additional clinical data expected from various oncology programs, a critical focus for ImmunityBio will be translating its clinical successes into further regulatory approvals.